Pulmonary Arterial Hypertension - Epidemiology Forecast to 2028

"Pulmonary Arterial Hypertension - Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Pulmonary Arterial Hypertension epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2016-2028

Pulmonary Arterial Hypertension Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Pulmonary Arterial Hypertension in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders views are also taken into account to provide a deep understanding of the Pulmonary Arterial Hypertension outlook. It also includes the explanation of changing trends of epidemiology outlining the Pulmonary Arterial Hypertension scenario.

Pulmonary Arterial Hypertension Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Pulmonary Arterial Hypertension thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Pulmonary Arterial Hypertension Report assesses the disease risk and burden and highlights the unmet needs
It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
10 Year Forecast
7MM Coverage
Total Cases in Pulmonary Arterial Hypertension

Key assessments
Patient Segmentation in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Risk & Burden
Factors driving growth in a specific Pulmonary Arterial Hypertension patient population

1. Report Introduction
2. Pulmonary Arterial Hypertension Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Pulmonary Arterial Hypertension in 2016
2.2. Patient Share Distribution of Pulmonary Arterial Hypertension in 2028
3. Disease Background and Overview: Pulmonary Arterial Hypertension
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Pulmonary Arterial Hypertension in 7MM
4.3. Total Prevalent/ Incident Patient Population of Pulmonary Arterial Hypertension in 7MM By Countries
5. Epidemiology of Pulmonary Arterial Hypertension by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.1.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.1.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.1.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.4.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.4.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.4.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.5.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.5.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.5.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.6.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.6.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.6.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.7.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.7.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.7.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.8.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.8.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.8.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension
5.9.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension *
5.9.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension *
5.9.5. Diagnosed Cases of the Pulmonary Arterial Hypertension
6. Unmet Needs of the Pulmonary Arterial Hypertension
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List Of Tables

Table 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in 7MM
Table 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)*
Table 6: Diagnosed Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in France (2016-2028)
Table 12: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in France (2016-2028) *
Table 13: Sex- Specific Cases of the Pulmonary Arterial Hypertension in France (2016-2028) *
Table 14: Diagnosed Cases of the Pulmonary Arterial Hypertension in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension in UK (2016-2028) *
Table 26: Diagnosed Cases of the Pulmonary Arterial Hypertension in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028)

List Of Figures

Figure 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in 7MM
Figure 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Pulmonary Arterial Hypertension in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Pulmonary Arterial Hypertension in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Pulmonary Arterial Hypertension in France (2016-2028) *
Figure 14: Diagnosed Cases of the Pulmonary Arterial Hypertension in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Pulmonary Arterial Hypertension in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Pulmonary Arterial Hypertension in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Pulmonary Arterial Hypertension in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Pulmonary Arterial Hypertension in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Pulmonary Arterial Hypertension in Japan (2016-2028)

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available